Alnylam chalks up another win with trial of a liver-disease drug – STAT
The drug, based on RNA interference technology, silences a gene critical to the development of damaging and painful kidney stones.
Related Articles
To prevent ovarian cancers, fallopian tube removal is on the rise
To prevent ovarian cancers, fallopian tube removal is on an upsurge — and diagnostic manuals are finally catching up.
I’m a fertility doctor, and I think IVF needs more regulation
An IVF doctor and clinic founder writes that his industry needs increased governmental oversight and more comprehensive regulations, not less.
Even full fetal personhood shouldn’t end abortion rights
The law shouldn’t force pregnant people to assume greater duties to their fetuses than parents have to their children.
Medicare Advantage’s supplemental benefits will cost taxpayers $86 billion this year, with little transparency
Taxpayers will send an estimated $86 billion to Medicare Advantage insurers this year to pay for supplemental benefits for their members, or 17% of total
A closer look at the new members of the CDC vaccine advisory panel
For more than a half-century, the Centers for Disease Control and Prevention have relied on outside experts to guide the agency’s recommendations on how
I’m adopted. I still won’t use genetic testing services like 23andMe
A company like 23andMe can answer a lot of questions for an adoptee. But those answers come with a high cost to privacy.
Why autism researchers aren’t convinced NIH can keep science and politics separate
A new $50 million NIH initiative to find the causes of autism faces questions about transparency and independence.
Sarepta reports second patient death after treatment with Duchenne gene therapy
Sarepta said it was halting shipments of its Duchenne gene therapy for patients who can no longer walk, following the death of a second recipient.
Get 50% off an annual STAT+ subscription
Join the STAT+ community today and enjoy unlimited access to award-winning journalism, premium data tools, discounted event tickets, and much more.
In fight over research overhead funding, universities propose alternatives to Trump’s cuts
Exclusive: Facing NIH cuts in “indirect cost” funding, universities float new models to streamline requests and ensure support for research overhead, labs, and federal grants.